Every round on record, with the sources behind each and the investors on them.
Develops and manufactures precision devices for administering pharmaceutical treatments
enjosim.comShanghai, ChinaMedtechFounded 2021
2 sources · checked 1 time, last 3h ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Source 2 is a roundup; its November 2 date is used for the announcement date. It writes the amount as RMB 200 million, while the more specific Source 1 writes 200 million yuan, which is used.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $30.1M RMB 200 million | ~ 2026-11-02 | not stated | 2 outlets. #31 in Trending |
2 sources · checked 1 time, last 3h ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 2 sources Source 2 is a roundup; its November 2 date is used for the announcement date. It writes the amount as RMB 200 million, while the more specific Source 1 writes 200 million yuan, which is used. | ||||
Yingjiexin Medical designs and manufactures high-precision self-administration drug-delivery devices, especially customized injection pens and auto-injectors for biopharmaceutical companies making drugs such as GLP-1 therapies, insulin, and growth hormone.
Yingjiexin is targeting a supply gap in a device market that the company says was historically dominated by overseas players, offering customized high-precision pens for GLP-1 therapies, insulin, growth hormone and other biologics while serving dozens of large biopharma companies. The RMB 200 million B round matters because the company says it will use the money to scale global production and delivery, develop next-generation self-administration devices, and fund overseas registration, market expansion and customer service.
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Pre-A轮 | 数千万元 | 2024-01-15 | 光速光合 | |